| Mutational spectrum, copy number changes, and outcome: results of a sequencing study of patients with newly diagnosed myeloma BA Walker, EM Boyle, CP Wardell, A Murison, DB Begum, NM Dahir, ... Journal of clinical oncology 33 (33), 3911-3920, 2015 | 660 | 2015 |
| Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation E Zamagni, F Patriarca, C Nanni, B Zannetti, E Englaro, A Pezzi, ... Blood, The Journal of the American Society of Hematology 118 (23), 5989-5995, 2011 | 601 | 2011 |
| A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the … E Zamagni, C Nanni, F Patriarca, E Englaro, P Castellucci, O Geatti, ... Haematologica 92 (1), 50-55, 2007 | 435 | 2007 |
| Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with … M Cavo, L Pantani, MT Petrucci, F Patriarca, E Zamagni, D Donnarumma, ... Blood, The Journal of the American Society of Hematology 120 (1), 9-19, 2012 | 390* | 2012 |
| Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms BA Walker, CP Wardell, L Melchor, A Brioli, DC Johnson, MF Kaiser, ... Leukemia 28 (2), 384-390, 2014 | 351 | 2014 |
| Single-cell genetic analysis reveals the composition of initiating clones and phylogenetic patterns of branching and parallel evolution in myeloma L Melchor, A Brioli, CP Wardell, A Murison, NE Potter, MF Kaiser, ... Leukemia 28 (8), 1705-1715, 2014 | 288 | 2014 |
| Translocations at 8q24 juxtapose MYC with genes that harbor superenhancers resulting in overexpression and poor prognosis in myeloma patients BA Walker, CP Wardell, A Brioli, E Boyle, MF Kaiser, DB Begum, NB Dahir, ... Blood cancer journal 4 (3), e191-e191, 2014 | 221 | 2014 |
| Global methylation analysis identifies prognostically important epigenetically inactivated tumor suppressor genes in multiple myeloma MF Kaiser, DC Johnson, P Wu, BA Walker, A Brioli, F Mirabella, ... Blood, The Journal of the American Society of Hematology 122 (2), 219-226, 2013 | 202 | 2013 |
| PET/CT improves the definition of complete response and allows to detect otherwise unidentifiable skeletal progression in multiple myeloma E Zamagni, C Nanni, K Mancuso, P Tacchetti, A Pezzi, L Pantani, ... Clinical Cancer Research 21 (19), 4384-4390, 2015 | 184 | 2015 |
| The impact of intra‐clonal heterogeneity on the treatment of multiple myeloma A Brioli, L Melchor, M Cavo, GJ Morgan British journal of haematology 165 (4), 441-454, 2014 | 141 | 2014 |
| Contrast enhanced MRI and 18F-FDG PET-CT in the assessment of multiple myeloma: a comparison of results in different phases of the disease P Spinnato, A Bazzocchi, A Brioli, C Nanni, E Zamagni, U Albisinni, ... European journal of radiology 81 (12), 4013-4018, 2012 | 123 | 2012 |
| Superior complete response rate and progression-free survival after autologous transplantation with up-front velcade-thalidomide-dexamethasone compared with thalidomide … M Cavo, P Tacchetti, F Patriarca, MT Petrucci, L Pantani, M Ceccolini, ... Blood 112 (11), 158, 2008 | 114 | 2008 |
| Multiple myeloma, venous thromboembolism, and treatment-related risk of thrombosis E Zamagni, A Brioli, P Tacchetti, B Zannetti, L Pantani, M Cavo Seminars in thrombosis and hemostasis 37 (03), 209-219, 2011 | 109 | 2011 |
| Coexistent hyperdiploidy does not abrogate poor prognosis in myeloma with adverse cytogenetics and may precede IGH translocations C Pawlyn, L Melchor, A Murison, CP Wardell, A Brioli, EM Boyle, ... Blood, The Journal of the American Society of Hematology 125 (5), 831-840, 2015 | 106 | 2015 |
| Bortezomib (Velcade (R))-thalidomide-dexamethasone (VTD) vs thalidomide-dexamethasone (TD) in preparation for autologous stem-cell (SC) transplantation (ASCT) in newly … M Cavo, F Patriarca, P Tacchetti, M Galli, G Perrone, MT Petrucci, A Brioli, ... Blood 110 (11), 30A-30A, 2007 | 102 | 2007 |
| The value of 18F-FDG PET/CT after autologous stem cell transplantation (ASCT) in patients affected by multiple myeloma (MM): experience with 77 patients C Nanni, E Zamagni, M Celli, P Caroli, V Ambrosini, P Tacchetti, A Brioli, ... Clinical nuclear medicine 38 (2), e74-e79, 2013 | 87 | 2013 |
| Short-term thalidomide incorporated into double autologous stem-cell transplantation improves outcomes in comparison with double autotransplantation for multiple myeloma M Cavo, F Di Raimondo, E Zamagni, F Patriarca, P Tacchetti, AF Casulli, ... Journal of clinical oncology 27 (30), 5001-5007, 2009 | 85 | 2009 |
| Bortezomib-thalidomide-dexamethasone (VTD) is superior to bortezomib-cyclophosphamide-dexamethasone (VCD) as induction therapy prior to autologous stem cell transplantation in … M Cavo, L Pantani, A Pezzi, MT Petrucci, F Patriarca, F Di Raimondo, ... Leukemia 29 (12), 2429-2431, 2015 | 84 | 2015 |
| Therapeutic targeting of hypoxia and hypoxia-inducible factor 1 alpha in multiple myeloma E Borsi, C Terragna, A Brioli, P Tacchetti, M Martello, M Cavo Translational Research 165 (6), 641-650, 2015 | 79 | 2015 |
| Serum free immunoglobulin light chain evaluation as a marker of impact from intraclonal heterogeneity on myeloma outcome A Brioli, H Giles, C Pawlyn, JP Campbell, MF Kaiser, L Melchor, ... Blood, The Journal of the American Society of Hematology 123 (22), 3414-3419, 2014 | 78 | 2014 |
